BioMarin to pay $4.8B for Amicus and its rare disease drugs

BioMarin plans to dish out $4.8 billion to acquire Amicus Therapeutics and its two approved rare disease medicines, the California biotech said Friday.

By gaining access to Amicus’ meds for Pompe …

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registeration number 16808844